Journal Article

Arylimidamides Have Potential for Chemoprophylaxis against Blood-Transmitted Chagas Disease

Batista, Marcos Meuser, Timm, Bruno Lisboa, Correia Soeiro, Maria de Nazaré, Boykin, David W., De Koning, Harry P., da Gama, Aline Nefertiti Silva, Batista, Denise da Gama Jaén

2023

Overview

Chagas disease (CD) affects over 6 million people worldwide and can be transmitted iatrogenically. Crystal violet (CV) was previously used for pathogen reduction but has harmful side-effects. In the present study, three arylimidamides (AIAs) and CV were used to sterilize mice blood samples experimentally contaminated with bloodstream trypomastigotes (BT) of Trypanosoma cruzi, at non hemolytic doses. All AIAs were not toxic to mouse blood cells until the highest tested concentration (96 µM). The previous treatment of BT with the AIAs impaired the infection establishment of cardiac cell cultures. In vivo assays showed that pre-incubation of mouse blood samples with the AIAs and CV (96 µM) significantly suppressed the parasitemia peak, but only the AIA DB1831 gave ≥90% animal survival, while vehicle treated samples reached 0%. Our findings support further studies regarding the potential use of AIAs for blood bank purposes.

• Publisher: MDPI AG,MDPI
• Subject: adverse effects / arylimidamides / Asymptomatic / Biocompatibility / blood / Blood & organ donations / blood bank / Blood banks / Blood cells / blood flow / Blood transfusions / Care and treatment / Chagas disease / Chemoprevention / chemoprophylaxis / Complications and side effects / Disease transmission / Food contamination & poisoning / Gentian violet / Health services / Iatrogenesis / Infections / mice / Microscopy / Parasitemia / Parasites / Pathogens / Patient outcomes / Prevention / Properties / Protozoa / Public health / toxicity / Tropical diseases / Trypanosoma cruzi / Trypomastigotes / Vector-borne diseases